Airway Basal Cell Differentiation from Pluripotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to generate a reliable population of human-derived airway basal cells that accurately recapitulate the physiology and pathophysiology of native airway epithelial barriers, and there is a need for cells that can be expanded and maintained long-term for respiratory disease modeling without harsh isolation protocols.
Innovation Solution
A method involving culturing Nkx2-1+ lung progenitor cells in specific culture media with Wnt agonists, retinoic acid, and BMP agonists, followed by differentiation into airway basal cells using fibroblast growth factors and Rho kinase inhibitors, allowing for expansion and cryopreservation of airway basal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If harsh cell isolation protocols are used to obtain primary human bronchial epithelial cells, then cell population can be accessed, but cell viability and physiological function are compromised
Solution Approach 1:
The patent applies preliminary action by differentiating pluripotent stem cells into airway basal cells before they are needed for experimentation. This creates a ready-to-use cell population that eliminates the need for harsh isolation protocols when primary cells are required, preserving both cell quantity and physiological function.
Solution Approach 2:
The patent creates a copy of primary airway basal cells through stem cell differentiation. These differentiated cells replicate the physiological properties of primary basal cells without requiring harsh isolation procedures, thus maintaining both sufficient cell population and reliable physiological function for disease modeling.
2Quantity of substance
If primary human bronchial epithelial cells are obtained via bronchoscopy or explanted lungs, then patient-specific cells can be accessed, but the process is invasive and limited in capacity
Solution Approach 1:
The patent creates patient-specific airway basal cells by differentiating induced pluripotent stem cells (iPSCs) derived from patient biopsies. This copying approach allows unlimited expansion of cells without repeated invasive procedures, providing both sufficient cell capacity and ease of operation for longitudinal studies.
Solution Approach 2:
The patent performs preliminary differentiation of iPSCs into airway basal cells that can be cryopreserved and expanded indefinitely. This eliminates the need for repeated invasive sampling, providing unlimited cell capacity while simplifying subsequent experimental operations.
3Productivity
If standard differentiation protocols are used to generate airway cells from PSCs, then cell production can be achieved, but the cells fail to recapitulate native airway epithelial barrier physiology
Solution Approach 1:
The patent applies parameter changes by systematically optimizing differentiation culture conditions including specific growth factors (BMP4, FGF7, FGF10), their concentrations, and timing sequences. These parameter adjustments enable the generation of airway basal cells that both maintain high productivity and accurately recapitulate native airway epithelial barrier physiology.
Solution Approach 2:
The patent applies local quality by directing differentiation toward specific cell fates using spatially and temporally controlled exposure to differentiation factors. This ensures that the generated airway basal cells possess the precise physiological characteristics needed for accurate disease modeling while maintaining efficient production.
4Quantity of substance
If airway basal cells are expanded long-term in culture, then sufficient cell numbers for disease modeling can be obtained, but cell phenotype and function may drift
Solution Approach 1:
The patent applies self-service by establishing culture conditions that enable airway basal cells to maintain their phenotype and self-renewal capacity through controlled differentiation factor exposure. This allows long-term expansion sufficient for disease modeling while preserving cellular identity and function.
Solution Approach 2:
The patent applies feedback by monitoring cell phenotype markers during expansion and adjusting differentiation factor concentrations accordingly. This feedback control ensures that cell numbers increase sufficiently for disease modeling while maintaining stable cellular composition and preventing phenotype drift.
Data Source
AI summary
Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.